Delivering anti‐VEGF‐A treatment at a time when VEGF‐A levels are peaking in the plasma and skin of patients with psoriasis may enhance the efficacy of anti‐VEGF‐A therapy in psoriasis and could help minimise toxic effects. The gene discussed is VEGFA; the disease is psoriasis.